E
KRON

Ergoteles’s Kronos Bio KRON Stock Holding History

Ergoteles’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,457
Closed -$23.1K – 481
2023
Q2 		$23.1K Buy
+13,457
New +$21.4K ﹤0.01% 983
2023
Q1 		– Sell
-46,389
Closed -$75.2K – 1516
2022
Q4 		$75.2K Buy
+46,389
New +$107K ﹤0.01% 1257
2022
Q3 		– Sell
-76,000
Closed -$277K – 1775
2022
Q2 		$277K Buy
76,000
+44,100
+138% +$200K 0.01% 1147
2022
Q1 		$231K Buy
+31,900
New +$272K 0.01% 930

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's KRON Position: Q3 2023 in Review

Ergoteles sold out of Kronos Bio (KRON) in Q3 2023, closing a stake of 13,457 shares — an estimated $23.1K sold.

Ergoteles first reported a position in KRON in Q1 2022 and held it in 4 quarters. The position peaked at $277K in Q2 2022. 63 funds tracked by Wall St. Rank hold KRON as of Q3 2023.

  • Ergoteles reported no remaining Kronos Bio position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 13,457 Kronos Bio shares in Q3 2023, an estimated $23.1K.
  • Ergoteles first reported a position in Kronos Bio in Q1 2022 and held it in 4 quarters.
  • Ergoteles's Kronos Bio position peaked at $277K in Q2 2022.
  • 63 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.